Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update

Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update GlobeNewswire October 21, 2025 SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) — Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of […]

Eagle Pharmaceuticals Announces Results of 2025 Annual Meeting of Stockholders

(OtherOTC:EGRX),(OTC US:EGRX), WOODCLIFF LAKE, N.J., Oct. 21, 2025 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) is pleased to announce the voting results for each of the matters presented at the Company's 2025 annual meeting of stockholders (the “Annual Meeting”) held virtually on Friday, October 17, 2025. Of the 13,157,754 shares

Inotiv, Inc. to Participate in Three Investor Conferences in November 2025

(NASDAQ:NOTV), WEST LAFAYETTE, Ind., Oct. 21, 2025 (GLOBE NEWSWIRE) — Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor,

Getty Realty Corp. Announces Increased Quarterly Cash Dividend

(NYSE:GTY), NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) — Getty Realty Corp. (NYSE: GTY) (“Getty” or the “Company”), a net lease REIT focused on convenience and automotive retail real estate, announced today that its Board of Directors declared a cash dividend of $0.485 per common share, an increase of 3.2% over the previous quarterly dividend.

Inspired to Report Third Quarter 2025 Results and Hold Conference Call on November 5

(NASDAQ:INSE), NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) — Inspired Entertainment, Inc. (“Inspired” or the “Company”) (NASDAQ: INSE), a leading B2B provider of gaming content, technology, hardware and services, announced that it will report financial results for the third quarter ended September 30, 2025 before the market opens on Wednesday, November 5, 2025. Inspired management

Hanmi Reports 2025 Third Quarter Results

(NASDAQ:HAFC), LOS ANGELES, Oct. 21, 2025 (GLOBE NEWSWIRE) — Hanmi Financial Corporation (NASDAQ: HAFC or “Hanmi”), the parent company of Hanmi Bank (the “Bank”), today reported financial results for the third quarter of 2025. Net income for the third quarter of 2025 was $22.1 million, or $0.73 per diluted share, compared with $15.1 million, or

Bitfarms Announces Closing of US$500 Million of Convertible Senior Notes

(TSX:BITF),(NasdaqGM:BITF), Opportunistic capital raise for general corporate purposes Bitfarms used cash on hand to purchase capped calls to offset economic dilution up to a cap of 125% premium to the last reported sale price of Bitfarms' common shares on Nasdaq on the date of pricing TORONTO, Ontario and NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE)

Vicor Corporation Reports Results for the Third Quarter Ended September 30, 2025

(NASDAQ:VICR), ANDOVER, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: VICR) today reported financial results for the third quarter ended September 30, 2025. These results will be discussed later today at 5:00 p.m. Eastern Time, during management's quarterly investor conference call. The details for the call are below. Product revenues and licensing income

MARA Schedules Conference Call for Third Quarter 2025 Financial Results

(NASDAQ:MARA), Earnings Webcast and Conference Call Set for Tuesday, November 4, 2025 at 5:00 p.m. ET Miami, FL, Oct. 21, 2025 (GLOBE NEWSWIRE) — MARA Holdings, Inc. (NASDAQ: MARA) (“MARA” or the “Company”), a leading digital energy and infrastructure company, will hold a webcast and conference call on Tuesday, November 4, 2025 at 5:00 p.m.

Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity

(NASDAQ:TERN), Results show maximum placebo-adjusted weight loss of 4.6% with 12% treatment discontinuation due to adverse events Asymptomatic, reversible grade 3 liver enzyme elevations occurred in three participants during post-treatment follow-up period, two of which were deemed drug related Company will not advance TERN-601 or invest in other metabolic assets Reiterates focus on TERN-701, a

Scroll to Top